A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

Title

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

Authors

Keywords

Phosphatidylinositol 3-kinase, Non–small cell lung, Bevacizumab, Paclitaxel, Carboplatin, Cisplatin, Pemetrexed, Metastatic NSCLC, Front-line NSCLC, First-line NSCLC

Journal

EUROPEAN JOURNAL OF CANCER

Volume 86, Issue -, Pages 186-196

Publisher

Elsevier BV

Online

2017-10-12

DOI

10.1016/j.ejca.2017.08.027